Related Experiment Video
Updated: Apr 12, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.4K
Molecular targets in glioblastoma
Maira Zorzan1, Enrico Giordan, Marco Redaelli
1Department of Molecular Medicine, University of Padova, Padova, Italy.
Future Oncology (London, England)
|May 9, 2015
Summary
Glioblastoma, a lethal brain tumor, has poor outcomes due to resistance and location. Novel targeted therapies show promise for improving glioblastoma treatment success.
Area of Science:
- Neuro-oncology
- Molecular biology
- Genetics
Background:
- Glioblastoma is the most aggressive primary brain tumor with a poor prognosis.
- Treatment challenges include diffuse tumor margins, critical brain location, and chemo/radio-resistant cancer stem cells.
- Standard treatment involves surgery, radiotherapy, and temozolomide chemotherapy.
Purpose of the Study:
- To explore the role of molecular and genetic heterogeneity in glioblastoma.
- To introduce novel targeted therapies for glioblastoma treatment.
- To highlight emerging therapeutic strategies for glioblastoma.
Main Methods:
- Review of current glioblastoma pathogenesis understanding.
- Identification of key molecular targets and signaling pathways.
- Analysis of novel therapeutic approaches including small molecules, monoclonal antibodies, and RNA-based strategies (siRNA, antisense oligonucleotides, ribozymes).
Main Results:
- Understanding molecular and genetic heterogeneity is crucial for glioblastoma pathogenesis.
- Novel targeted therapies focus on specific signaling molecules and altered pathways.
- RNA-based strategies offer new avenues for glioblastoma treatment.
Conclusions:
- Emerging targeted therapies hold significant promise for improving glioblastoma treatment outcomes.
- Further research and clinical trials are needed to validate these novel approaches.
- Advances in understanding glioblastoma heterogeneity are driving therapeutic innovation.
